Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Mar;79(3):465-76.
doi: 10.1111/bcp.12512.

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease

Sigurd D Süssmuth  1 , Salman Haider, G Bernhard Landwehrmeyer, Ruth Farmer, Chris Frost, Giovanna Tripepi, Claus A Andersen, Marco Di Bacco, Claudia Lamanna, Enrica Diodato, Luisa Massai, Daniela Diamanti, Elisa Mori, Letizia Magnoni, Jens Dreyhaupt, Karin Schiefele, David Craufurd, Carsten Saft, Monika Rudzinska, Danuta Ryglewicz, Michael Orth, Sebastian Brzozy, Anna Baran, Giuseppe Pollio, Ralph Andre, Sarah J Tabrizi, Borje Darpo, Goran Westerberg; PADDINGTON Consortium
Affiliations
Randomized Controlled Trial

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease

Sigurd D Süssmuth et al. Br J Clin Pharmacol. 2015 Mar.

Abstract

Aims: Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington's disease (HD). This was the first study of selisistat in HD patients and was primarily aimed at development of pharmacodynamic biomarkers.

Methods: This was a randomized, double-blind, placebo-controlled, multicentre exploratory study. Fifty-five male and female patients in early stage HD were randomized to receive 10 mg or 100 mg of selisistat or placebo once daily for 14 days. Blood sampling, clinical and safety assessments were conducted throughout the study. Candidate pharmacodynamic markers included circulating soluble huntingtin and innate immune markers.

Results: Selisistat was found to be safe and well tolerated, and systemic exposure parameters showed that the average steady-state plasma concentration achieved at the 10 mg dose level (125 nm) was comparable with the IC50 for SirT1 inhibition. No adverse effects on motor, cognitive or functional readouts were recorded. While circulating levels of soluble huntingtin were not affected by selisistat in this study, the biological samples collected have allowed development of assay technology for use in future studies. No effects on innate immune markers were seen.

Conclusions: Selisistat was found to be safe and well tolerated in early stage HD patients at plasma concentrations within the anticipated therapeutic concentration range.

Keywords: Huntington's disease; SirT1 inhibition; pharmacodynamics; pharmacokinetics; selisistat.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Model predicted values and 95% confidence intervals of estimated log soluble Htt levels in peripheral blood mononuclear cells as a proportion of total protein by group at each time point. No statistically significant differences were observed between treatment groups at any time point. formula image, 10 mg selisistat; formula image, 100 mg selisistat; formula image, placebo. Model predicted values and 95% confidence intervals of estimated log plasma cytokine levels by group at each time point: (B) log IL-1, (C) log IL-6, (D) IL-8 and (E) TNF-α
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rubinsztein DC, Carmichael J. Huntington's disease: molecular basis of neurodegeneration. Expert Rev Mol Med. 2003;5:1–21. - PubMed
    1. van der Burg JM, Bjorkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009;8:765–774. - PubMed
    1. Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell MM, Reeves SA, Bates GP, Neri C, Thompson LM, Marsh JL, Kazantsev AG. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA. 2010;107:7927–7932. - PMC - PubMed
    1. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010;90:905–981. - PubMed
    1. Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C, Cipicchio PM, Lauver MA, Choi SH, Silverman RB, Ferrante RJ, Hersch S, Kazantsev AG. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2012;2:1492–1497. - PMC - PubMed

Publication types

MeSH terms